Skipping breast surgery after complete response
Part of Cancer clinical trials.
This trial looks at whether some people with breast cancer can safely avoid breast surgery after they respond completely to treatment before surgery. If you have no remaining cancer in the tissue and lymph node tests, this study checks whether the “watch-and-wait” approach is feasible and safe.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re an adult (over 18).
- You have breast cancer that is stage IIA to IIIA and is either triple-negative or HER2-positive (ER/PR can vary).
- You were able to do treatment before surgery (neoadjuvant systemic therapy) and you had no cancer found afterward (confirmed complete response).
- Your health status is good (ECOG 0–1), and you’re expected to live more than 3 months.
- You can have surgery safely if needed, and your liver and bone marrow tests are adequate.
- You agree to reliable birth control during the study and are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether older women with early-stage, slow-growing breast cancer can safely skip removal of underarm lymph nodes during surgery. The goal is to reduce surgery-related side effects while maintaining safety.
This trial tests whether some women with HER2-positive breast cancer can safely avoid breast surgery if their tumor nearly disappears after chemotherapy. It uses MRI and biopsy results to find people most likely to have no remaining cancer (pCR).
This trial tests whether women with certain aggressive breast cancers (HER2-positive without hormone receptors, or triple-negative) can safely skip breast surgery if chemotherapy makes their tumor completely disappear. The goal is to avoid surgery and its side effects when it may no longer be needed.
This trial studies a special vacuum-assisted biopsy taken just before breast surgery to see how well pre-surgery (neoadjuvant) chemotherapy worked. It may help doctors understand whether patients truly had a complete or near-complete response on scans, which can guide next steps.
This trial is testing whether some women with triple-negative breast cancer who have a complete response to chemo-immunotherapy can safely skip surgery. It is for women whose cancer completely disappeared after treatment, as shown on MRI and biopsy.
This trial checks if a breast biopsy can confirm that chemo has destroyed all cancer cells, so you might avoid surgery altogether. It's for people with aggressive breast cancer types who responded well to chemotherapy.
Hear when a new Refusal of Breast Surgery in Patients With Breast Cancer With a cCR After NST and a Confirmed Pathological Complete Response (pCR) Using VAB and SLNB trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.